DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body.
Geographically, North America and Europe dominates the global market for DPP IV inhibitors due to high prevalence rate and rising awareness among people about the DPP IV inhibitors. Asia-Pacific is considered as a fastest growing market due to increasing obese population.
In 2019, the market size of DPP IV Inhibitors (DPP-4 Inhibitors) is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for DPP IV Inhibitors (DPP-4 Inhibitors).
This report studies the global market size of DPP IV Inhibitors (DPP-4 Inhibitors), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the DPP IV Inhibitors (DPP-4 Inhibitors) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
AstraZeneca
Boehringer
Eli Lilly
Merck
Mitsubishi Tanabe Pharma
Novartis
Takeda
...
Market Segment by Product Type
Sitagliptin
Vildagliptin
Saxagliptin
Linagliptin
Others
Market Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the DPP IV Inhibitors (DPP-4 Inhibitors) status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key DPP IV Inhibitors (DPP-4 Inhibitors) manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of DPP IV Inhibitors (DPP-4 Inhibitors) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Geographically, North America and Europe dominates the global market for DPP IV inhibitors due to high prevalence rate and rising awareness among people about the DPP IV inhibitors. Asia-Pacific is considered as a fastest growing market due to increasing obese population.
In 2019, the market size of DPP IV Inhibitors (DPP-4 Inhibitors) is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for DPP IV Inhibitors (DPP-4 Inhibitors).
This report studies the global market size of DPP IV Inhibitors (DPP-4 Inhibitors), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the DPP IV Inhibitors (DPP-4 Inhibitors) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
AstraZeneca
Boehringer
Eli Lilly
Merck
Mitsubishi Tanabe Pharma
Novartis
Takeda
...
Market Segment by Product Type
Sitagliptin
Vildagliptin
Saxagliptin
Linagliptin
Others
Market Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the DPP IV Inhibitors (DPP-4 Inhibitors) status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key DPP IV Inhibitors (DPP-4 Inhibitors) manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of DPP IV Inhibitors (DPP-4 Inhibitors) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Size Growth Rate by Type (2019-2025)
1.3.2 Sitagliptin
1.3.3 Vildagliptin
1.3.4 Saxagliptin
1.3.5 Linagliptin
1.3.6 Others
1.4 Market Segment by Application
1.4.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Share by Application (2019-2025)
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Size
2.1.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Revenue 2014-2025
2.1.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales 2014-2025
2.2 DPP IV Inhibitors (DPP-4 Inhibitors) Growth Rate by Regions
2.2.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Regions 2014-2019
2.2.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Manufacturers
3.1.1 DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Manufacturers 2014-2019
3.1.2 DPP IV Inhibitors (DPP-4 Inhibitors) Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 DPP IV Inhibitors (DPP-4 Inhibitors) Revenue by Manufacturers (2014-2019)
3.2.2 DPP IV Inhibitors (DPP-4 Inhibitors) Revenue Share by Manufacturers (2014-2019)
3.2.3 Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Concentration Ratio (CR5 and HHI)
3.3 DPP IV Inhibitors (DPP-4 Inhibitors) Price by Manufacturers
3.4 Key Manufacturers DPP IV Inhibitors (DPP-4 Inhibitors) Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into DPP IV Inhibitors (DPP-4 Inhibitors) Market
3.6 Key Manufacturers DPP IV Inhibitors (DPP-4 Inhibitors) Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Sitagliptin Sales and Revenue (2014-2019)
4.1.2 Vildagliptin Sales and Revenue (2014-2019)
4.1.3 Saxagliptin Sales and Revenue (2014-2019)
4.1.4 Linagliptin Sales and Revenue (2014-2019)
4.1.5 Others Sales and Revenue (2014-2019)
4.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales Market Share by Type
4.3 Global DPP IV Inhibitors (DPP-4 Inhibitors) Revenue Market Share by Type
4.4 DPP IV Inhibitors (DPP-4 Inhibitors) Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Application
6 United States
6.1 United States DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Company
6.2 United States DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Type
6.3 United States DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Application
7 European Union
7.1 European Union DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Company
7.2 European Union DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Type
7.3 European Union DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Application
8 China
8.1 China DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Company
8.2 China DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Type
8.3 China DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Application
9 Rest of World
9.1 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Company
9.2 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Type
9.3 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Application
9.4 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Countries
9.4.1 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Countries
9.4.2 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.1.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.1.5 AstraZeneca Recent Development
10.2 Boehringer
10.2.1 Boehringer Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.2.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.2.5 Boehringer Recent Development
10.3 Eli Lilly
10.3.1 Eli Lilly Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.3.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.3.5 Eli Lilly Recent Development
10.4 Merck
10.4.1 Merck Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.4.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.4.5 Merck Recent Development
10.5 Mitsubishi Tanabe Pharma
10.5.1 Mitsubishi Tanabe Pharma Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.5.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.5.5 Mitsubishi Tanabe Pharma Recent Development
10.6 Novartis
10.6.1 Novartis Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.6.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.6.5 Novartis Recent Development
10.7 Takeda
10.7.1 Takeda Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.7.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.7.5 Takeda Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 DPP IV Inhibitors (DPP-4 Inhibitors) Sales Channels
11.2.2 DPP IV Inhibitors (DPP-4 Inhibitors) Distributors
11.3 DPP IV Inhibitors (DPP-4 Inhibitors) Customers
12 Market Forecast
12.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales and Revenue Forecast 2019-2025
12.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales Forecast by Type
12.3 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales Forecast by Application
12.4 DPP IV Inhibitors (DPP-4 Inhibitors) Forecast by Regions
12.4.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales Forecast by Regions 2019-2025
12.4.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Size Growth Rate by Type (2019-2025)
1.3.2 Sitagliptin
1.3.3 Vildagliptin
1.3.4 Saxagliptin
1.3.5 Linagliptin
1.3.6 Others
1.4 Market Segment by Application
1.4.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Share by Application (2019-2025)
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Size
2.1.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Revenue 2014-2025
2.1.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales 2014-2025
2.2 DPP IV Inhibitors (DPP-4 Inhibitors) Growth Rate by Regions
2.2.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Regions 2014-2019
2.2.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Manufacturers
3.1.1 DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Manufacturers 2014-2019
3.1.2 DPP IV Inhibitors (DPP-4 Inhibitors) Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 DPP IV Inhibitors (DPP-4 Inhibitors) Revenue by Manufacturers (2014-2019)
3.2.2 DPP IV Inhibitors (DPP-4 Inhibitors) Revenue Share by Manufacturers (2014-2019)
3.2.3 Global DPP IV Inhibitors (DPP-4 Inhibitors) Market Concentration Ratio (CR5 and HHI)
3.3 DPP IV Inhibitors (DPP-4 Inhibitors) Price by Manufacturers
3.4 Key Manufacturers DPP IV Inhibitors (DPP-4 Inhibitors) Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into DPP IV Inhibitors (DPP-4 Inhibitors) Market
3.6 Key Manufacturers DPP IV Inhibitors (DPP-4 Inhibitors) Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Sitagliptin Sales and Revenue (2014-2019)
4.1.2 Vildagliptin Sales and Revenue (2014-2019)
4.1.3 Saxagliptin Sales and Revenue (2014-2019)
4.1.4 Linagliptin Sales and Revenue (2014-2019)
4.1.5 Others Sales and Revenue (2014-2019)
4.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales Market Share by Type
4.3 Global DPP IV Inhibitors (DPP-4 Inhibitors) Revenue Market Share by Type
4.4 DPP IV Inhibitors (DPP-4 Inhibitors) Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Application
6 United States
6.1 United States DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Company
6.2 United States DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Type
6.3 United States DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Application
7 European Union
7.1 European Union DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Company
7.2 European Union DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Type
7.3 European Union DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Application
8 China
8.1 China DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Company
8.2 China DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Type
8.3 China DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Application
9 Rest of World
9.1 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Company
9.2 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Type
9.3 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Application
9.4 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Breakdown Data by Countries
9.4.1 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Sales by Countries
9.4.2 Rest of World DPP IV Inhibitors (DPP-4 Inhibitors) Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.1.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.1.5 AstraZeneca Recent Development
10.2 Boehringer
10.2.1 Boehringer Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.2.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.2.5 Boehringer Recent Development
10.3 Eli Lilly
10.3.1 Eli Lilly Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.3.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.3.5 Eli Lilly Recent Development
10.4 Merck
10.4.1 Merck Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.4.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.4.5 Merck Recent Development
10.5 Mitsubishi Tanabe Pharma
10.5.1 Mitsubishi Tanabe Pharma Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.5.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.5.5 Mitsubishi Tanabe Pharma Recent Development
10.6 Novartis
10.6.1 Novartis Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.6.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.6.5 Novartis Recent Development
10.7 Takeda
10.7.1 Takeda Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of DPP IV Inhibitors (DPP-4 Inhibitors)
10.7.4 DPP IV Inhibitors (DPP-4 Inhibitors) Product Introduction
10.7.5 Takeda Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 DPP IV Inhibitors (DPP-4 Inhibitors) Sales Channels
11.2.2 DPP IV Inhibitors (DPP-4 Inhibitors) Distributors
11.3 DPP IV Inhibitors (DPP-4 Inhibitors) Customers
12 Market Forecast
12.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales and Revenue Forecast 2019-2025
12.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales Forecast by Type
12.3 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales Forecast by Application
12.4 DPP IV Inhibitors (DPP-4 Inhibitors) Forecast by Regions
12.4.1 Global DPP IV Inhibitors (DPP-4 Inhibitors) Sales Forecast by Regions 2019-2025
12.4.2 Global DPP IV Inhibitors (DPP-4 Inhibitors) Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
